全球高磷酸鹽血症市場：各地區分析與預測（2025-2035）

全球高磷酸鹽血症市場目前正處於生命週期的成長階段，其特徵是需求不斷擴大和腎臟疾病治療方案不斷增加。

這種成長主要是由於慢性腎臟病（CKD）盛行率的不斷上升，尤其是在老年人群中，以及人們日益認知到高磷酸鹽血症是 CKD 患者（尤其是接受透析治療的患者）的一種危重疾病。此外，FDA 等監管機構正在加快核准新治療方法，進一步推動市場擴張。隨著 CKD 患者數量的增加和更多治療方法進入市場，公司正專注於加強產品系列併改善已開發國家和新興國家的市場進入。隨著這些發展，市場預計將保持其成長軌跡，然而，隨著市場成熟，競爭加劇、學名藥增加和控制成本的壓力等因素可能會帶來挑戰。

影響

• 預計預測期內對高磷酸鹽血症治療的需求不斷增加將推動全球高磷酸鹽血症市場的成長。
• 由於診斷技術的進步、創新治療方法的發展以及患者和醫療保健專業人員意識的提高，全球高磷酸鹽血症市場預計將在未來顯著成長。

由於其先進的醫療保健基礎設施、高盛行率以及對疾病的高度認知，預計北美將在預測期內引領市場。此外，該地區擁有強大的製藥業，能夠儘早獲得有效的治療方法，從而進一步推動全球高磷酸鹽血症市場的成長。

本報告調查了全球高磷酸鹽血症市場，並總結了主要趨勢、影響市場的因素分析、法律制度、臨床試驗趨勢、市場規模趨勢和預測、各個細分市場、地區/主要國家的詳細分析、競爭格局和主要企業的概況。

目錄

執行摘要

第1章全球高磷酸鹽血症市場：產業展望

• 市場概況與生態系統
• 市場趨勢
• 高磷酸鹽血症的流行病學分析
• 臨床試驗
  • 按階段
  • 依贊助商類型
• 監管狀況/合規性
  • 美國法律要求與框架
  • 歐盟法律要求和框架
  • 亞太地區的法律要求與框架
• 市場動態
  • 影響分析
  • 市場促進因素
  • 市場限制
  • 市場機會

第2章 全球高磷酸鹽血症市場（按地區）

• 北美洲
• 歐洲
• 亞太地區
  • 市場動態
  • 市場規模及預測

第3章 全球高磷酸鹽血症市場：競爭基準化分析與公司概況

• 競爭格局
  • 各公司主要策略及發展
  • 重大進展分析
• 公司簡介
  • Kyowa Kirin, Inc.
  • Bayer
  • Unicycive Therapeutics
  • Sanofi
  • Shanghai Alebund Pharmaceuticals Limited
  • Ardelyx
  • Kissei Pharmaceutical Co. Ltd.
  • Astellas Pharma Inc.
  • Mitsubishi Tanabe Pharma Corporation

第4章調查方法

Market Lifecycle Stage

The global hyperphosphatemia market is currently in the growth stage of its lifecycle, marked by expanding demand and increasing renal treatment options. This growth is primarily driven by the rising prevalence of chronic kidney disease (CKD), particularly among aging populations, and the growing recognition of hyperphosphatemia as a critical condition in CKD patients, especially those on dialysis. Additionally, regulatory bodies such as the FDA are fast-tracking approvals for new treatments, which is fueling further market expansion. As the number of patients with CKD increases and more treatments enter the market, companies are focusing on enhancing their product portfolios and strengthening market access, both in developed and emerging markets. With these advancements, the market is expected to maintain its growth trajectory, although increased competition, rising generic alternatives, and cost containment pressures may pose challenges as the market matures.

Impact

• Increasing demand for hyperphosphatemia therapies is anticipated to support the growth of the global hyperphosphatemia market during the forecast period 2025-2035.
• The global hyperphosphatemia market is expected to grow at a significant rate due to advancements in diagnostic technologies, the development of innovative therapies, and increasing awareness among patients and healthcare providers.

North America is expected to dominate the global hyperphosphatemia market during the forecast period due to its advanced healthcare infrastructure, high prevalence, and increased awareness of the disease. The region also benefits from a strong pharmaceutical presence, which accelerates the availability of effective treatments and drives the growth of the global hyperphosphatemia market.

Recent Developments

• Regulatory Activities: In September 2024, Unicycive Therapeutics announced the submission of an NDA to the U.S. FDA for Oxylanthanum Carbonate, intended for the treatment of hyperphosphatemia in patients with chronic kidney disease undergoing dialysis.
• Regulatory Activities: In July 2024, the U.S. FDA expanded the approval of Velphoro (sucroferric oxyhydroxide) for use in patients as young as 9 years old. The drug, previously approved only for adults, is used to control serum phosphorus levels in patients with chronic kidney disease (CKD) undergoing dialysis.

Demand - Drivers and Limitations

Drivers:

• Rising Prevalence of Chronic Kidney Disease
• Continuous Advancements in Treatment Options

Challenges:

• Economic Barriers in Emerging Markets

How Can This Report Add Value to an Organization?

Product/Innovation Strategy: Product launches and innovations in the global hyperphosphatemia market are focused on advancing treatment options to improve patient care. These innovations aim to enhance the efficacy of therapies and streamline the detection and management of the disease. Key players in the market, such as Unicycive Therapeutics, have been involved in the development of therapies for hyperphosphatemia.

Competitive Strategy: Enterprises led by market leaders in the global hyperphosphatemia market are continuously working on updating their product portfolios with innovative treatments to maintain competitiveness. A detailed competitive benchmarking of the key players has been conducted, providing insights into how these companies compare in terms of product offerings, market share, and innovation. This benchmarking provides readers with a clear understanding of the market landscape and the positions of the leading players. Additionally, comprehensive competitive strategies, such as partnerships, agreements, and collaborations, will help readers identify untapped revenue opportunities in the market.

Key Market Players and Competition Synopsis

The companies that are profiled have been selected based on inputs gathered from primary experts and by analyzing company coverage, product portfolio, and market penetration.

Some of the prominent names established in this market are:

• Kyowa Kirin, Inc.
• Bayer
• Unicycive Therapeutics
• Sanofi
• Shanghai Alebund Pharmaceuticals Limited
• Ardelyx
• Kissei Pharmaceutical Co. Ltd.
• Astellas Pharma Inc.
• Mitsubishi Tanabe Pharma Corporation

Table of Contents

Executive Summary

Scope of Study

1. Global Hyperphosphatemia Market: Industry Outlook

• 1.1 Market Overview and Ecosystem
• 1.2 Market Trends
• 1.3 Epidemiological Analysis of Hyperphosphatemia
  • 1.3.1 By Region
• 1.4 Clinical Trials
  • 1.4.1 By Phase
  • 1.4.2 By Sponsor Type
• 1.5 Regulatory Landscape / Compliance
  • 1.5.1 Legal Requirement and Framework in the U.S.
  • 1.5.2 Legal Requirement and Framework in the E.U.
  • 1.5.3 Legal Requirement and Framework in Asia-Pacific
• 1.6 Market Dynamics
  • 1.6.1 Impact Analysis
  • 1.6.2 Market Drivers
  • 1.6.3 Market Restraints
  • 1.6.4 Market Opportunities

2. Global Hyperphosphatemia Market, By Region, $Million, 2023-2035

• 2.1 North America
  • 2.1.1 Market Dynamics
  • 2.1.2 Market Sizing and Forecast
    • 2.1.2.1 North America Hyperphosphatemia Market (by Country)
      • 2.1.2.1.1 U.S.
• 2.2 Europe
  • 2.2.1 Market Dynamics
  • 2.2.2 Market Sizing and Forecast
    • 2.2.2.1 Europe Hyperphosphatemia Market (by Country)
      • 2.2.2.1.1 U.K.
      • 2.2.2.1.2 Germany
      • 2.2.2.1.3 France
      • 2.2.2.1.4 Italy
• 2.3 Asia-Pacific
  • 2.3.1 Market Dynamics
  • 2.3.2 Market Sizing and Forecast
    • 2.3.2.1 Asia-Pacific Hyperphosphatemia Market (by Country)
      • 2.3.2.1.1 Japan

3. Global Hyperphosphatemia Market - Competitive Benchmarking and Company Profiles

• 3.1 Competitive Landscape
  • 3.1.1 Key Strategies and Developments by Company
    • 3.1.1.1 Funding Activities
    • 3.1.1.2 Mergers and Acquisitions
    • 3.1.1.3 Regulatory Approvals
    • 3.1.1.4 Partnerships, Collaborations and Business Expansions
  • 3.1.2 Key Developments Analysis
• 3.2 Company Profiles
  • 3.2.1 Kyowa Kirin, Inc.
    • 3.2.1.1 Company Overview
    • 3.2.1.2 Product Portfolio
    • 3.2.1.3 Target Customers/End Users
    • 3.2.1.4 Analyst View
  • 3.2.2 Bayer
    • 3.2.2.1 Company Overview
    • 3.2.2.2 Product Portfolio
    • 3.2.2.3 Target Customers/End Users
    • 3.2.2.4 Analyst View
  • 3.2.3 Unicycive Therapeutics
    • 3.2.3.1 Company Overview
    • 3.2.3.2 Product Portfolio
    • 3.2.3.3 Target Customers/End Users
    • 3.2.3.4 Analyst View
  • 3.2.4 Sanofi
    • 3.2.4.1 Company Overview
    • 3.2.4.2 Product Portfolio
    • 3.2.4.3 Target Customers/End Users
    • 3.2.4.4 Analyst View
  • 3.2.5 Shanghai Alebund Pharmaceuticals Limited
    • 3.2.5.1 Company Overview
    • 3.2.5.2 Product Portfolio
    • 3.2.5.3 Target Customers/End Users
    • 3.2.5.4 Analyst View
  • 3.2.6 Ardelyx
    • 3.2.6.1 Company Overview
    • 3.2.6.2 Product Portfolio
    • 3.2.6.3 Target Customers/End Users
    • 3.2.6.4 Analyst View
  • 3.2.7 Kissei Pharmaceutical Co. Ltd.
    • 3.2.7.1 Company Overview
    • 3.2.7.2 Product Portfolio
    • 3.2.7.3 Target Customers/End Users
    • 3.2.7.4 Analyst View
  • 3.2.8 Astellas Pharma Inc.
    • 3.2.8.1 Company Overview
    • 3.2.8.2 Product Portfolio
    • 3.2.8.3 Target Customers/End Users
    • 3.2.8.4 Analyst View
  • 3.2.9 Mitsubishi Tanabe Pharma Corporation
    • 3.2.9.1 Company Overview
    • 3.2.9.2 Product Portfolio
    • 3.2.9.3 Target Customers/End Users
    • 3.2.9.4 Analyst View

4. Research Methodology

List of Figures

• Figure: Global Hyperphosphatemia Market, Market Overview
• Figure: Global Hyperphosphatemia Market, Epidemiological Analysis, U.S.
• Figure: Global Hyperphosphatemia Market Coverage
• Figure: Global Hyperphosphatemia Market Key Trends, Impact Analysis, 2023-2035
• Figure: Global Hyperphosphatemia Market, Competitive Landscape, January 2022-April 2025

List of Tables

• Table: Global Hyperphosphatemia Market, Regulatory Scenario
• Table: Global Hyperphosphatemia Market Dynamics, Impact Analysis